A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection
Stopped Due to the COVID-19 pandemic, patient enrollment was slower than expected. After enrolling 26 patients, the trial was suspended as our partner company stopped producing haMPC-Exos.
Conditions
Interventions
- BIOLOGICAL: Dosage 1 of MPCs-derived exosomes
- BIOLOGICAL: Dosage 2 of MPCs-derived exosomes
- BIOLOGICAL: No MPCs-derived exosomes
Sponsor
Ruijin Hospital
Collaborators